China Market Entry for a Mid-Cap Indian Pharma Group

Challenge

A mid-cap Indian pharmaceutical company had identified significant demand for its oncology portfolio in China but faced a labyrinthine NMPA approval process, uncertainty around data localisation requirements, and no established distribution relationships. Previous attempts by two consulting firms had stalled at the regulatory stage after 18 months with no approvals.

Solution

We redesigned the regulatory pathway from scratch — engaging directly with NMPA consultants in Beijing and identifying an expedited approval track applicable to the client's molecule categories. Simultaneously, we identified and vetted three potential Chinese distribution partners, ultimately recommending a Tier-1 distributor with proven oncology networks. Our team provided Mandarin-language support throughout all regulatory submissions and partner negotiations.

Results

The first product received NMPA approval in 14 months — four months ahead of the revised target. The signed distribution agreement was the largest in the client's history. Year-1 China revenue reached USD 28M, exceeding the board's 3-year target in a single year. The client subsequently retained us for a Phase 2 expansion covering five additional product lines.